Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis
Zhenjie Wu(Second Military Medical University), Riccardo Autorino(Rush University Medical Center), Peter C. Black(University of British Columbia), M.C. Mir(Fundación Instituto Valenciano de Oncología), Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Le Qu(Nanjing University), Morgan Rouprêt(Sorbonne Université), Francesco Porpiglia(University of Turin), Asit K. Paul(Virginia Commonwealth University), Umberto Carbonara(University of Bari Aldo Moro), Andrea Necchi(Vita-Salute San Raffaele University), Sarah P. Psutka(University of Washington Medical Center), Linhui Wang(Second Military Medical University), Andrea Mari(Azienda Ospedaliero-Universitaria Careggi), Qi Chen(Nanchang University), Savio Domenico Pandolfo(University of Salerno), Mingmin Li(Nankai University)
Cited by 99
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
EAU Guidelines on Penile Cancer: 2014 Update
|European Urology|2014|594